DK3364993T3 - Fremgangsmåder til behandling af angelman syndrom - Google Patents
Fremgangsmåder til behandling af angelman syndrom Download PDFInfo
- Publication number
- DK3364993T3 DK3364993T3 DK16858443.1T DK16858443T DK3364993T3 DK 3364993 T3 DK3364993 T3 DK 3364993T3 DK 16858443 T DK16858443 T DK 16858443T DK 3364993 T3 DK3364993 T3 DK 3364993T3
- Authority
- DK
- Denmark
- Prior art keywords
- approaches
- treatment
- angelman syndrome
- angelman
- syndrome
- Prior art date
Links
- 208000009575 Angelman syndrome Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Fats And Perfumes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245038P | 2015-10-22 | 2015-10-22 | |
| PCT/US2016/058487 WO2017070680A1 (en) | 2015-10-22 | 2016-10-24 | Methods for treating angelman syndrome and related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3364993T3 true DK3364993T3 (da) | 2023-01-09 |
Family
ID=58558152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16858443.1T DK3364993T3 (da) | 2015-10-22 | 2016-10-24 | Fremgangsmåder til behandling af angelman syndrom |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11273218B2 (da) |
| EP (1) | EP3364993B1 (da) |
| JP (2) | JP6957460B2 (da) |
| AU (1) | AU2016341429B2 (da) |
| CA (1) | CA3002831C (da) |
| DK (1) | DK3364993T3 (da) |
| ES (1) | ES2936400T3 (da) |
| FI (1) | FI3364993T3 (da) |
| MX (1) | MX2018004947A (da) |
| WO (1) | WO2017070680A1 (da) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018000933A2 (pt) | 2015-07-17 | 2018-09-04 | Ovid Therapeutics Inc | métodos de tratamento de um distúrbio de desenvolvimento |
| ES2936400T3 (es) | 2015-10-22 | 2023-03-16 | Cavion Inc | Métodos para tratar el síndrome Angelman |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| KR20230050474A (ko) | 2016-08-11 | 2023-04-14 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| US11130750B2 (en) | 2017-02-15 | 2021-09-28 | Cavion, Inc. | Calcium channel inhibitors |
| SG10202111885PA (en) * | 2017-04-26 | 2021-12-30 | Cavion Inc | Methods for improving memory and cognition and for treating memory and cognitive disorders |
| WO2018200844A1 (en) * | 2017-04-26 | 2018-11-01 | Cavion, Inc. | Methods for treating dravet syndrome |
| US20200138921A1 (en) * | 2017-06-23 | 2020-05-07 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating diseases characterized by synaptic dysfunction and neurodegeneration including alzheimer's disease |
| US10420773B2 (en) | 2017-09-26 | 2019-09-24 | Ovid Therapeutics Inc. | Methods of treating developmental disorders and/or seizure disorders with etifoxine |
| KR20200116978A (ko) * | 2018-02-02 | 2020-10-13 | 베링거 인겔하임 인터내셔날 게엠베하 | 그렐린 o-아실 트랜스퍼라제(goat) 억제제로서의 벤질-치환된, (피리딘-3-일)메틸-치환된 또는 (피리딘-4-일)메틸-치환된 옥사디아졸로피리딘 유도체 |
| BR112020014436A2 (pt) | 2018-02-02 | 2020-12-01 | Boehringer Ingelheim International Gmbh | derivados de triazolopirimidina, composição farmacêutica e seus usos como inibidores de grelina o-acil transferase (goat) |
| CN108410824B (zh) * | 2018-03-14 | 2020-03-06 | 江南大学 | 一株氮哌酮单克隆抗体杂交瘤细胞株及其应用 |
| IL282006B2 (en) | 2018-10-03 | 2023-08-01 | Cavion Inc | Treatment of bone tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
| CA3118688A1 (en) * | 2018-11-05 | 2020-05-14 | Ovid Therapeutics Inc. | Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders |
| BR112021013766A2 (pt) | 2019-03-01 | 2021-09-21 | Flamel Ireland Limited | Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado |
| TWI870475B (zh) * | 2019-10-02 | 2025-01-21 | 美商卡凡恩公司 | 用於治療神經毒性之方法及材料 |
| WO2021126087A1 (en) | 2019-12-18 | 2021-06-24 | National University Of Singapore | Method for treating angelman syndrome and related disorders |
| KR20230018384A (ko) * | 2020-04-29 | 2023-02-07 | 프락시스 프리시젼 메디신즈, 인크. | T-형 칼슘 채널 조정제의 사용 방법 |
| ES2984466T3 (es) | 2020-05-22 | 2024-10-29 | Boehringer Ingelheim Int | Procedimiento de fabricación de 7-amino-5-metil-[1,2,5]oxadiazolo[3,4-b]piridín-carboxilato de alquilo |
| CN115916789B (zh) | 2020-05-22 | 2025-06-27 | 勃林格殷格翰国际有限公司 | 制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的连续方法 |
| WO2022109408A1 (en) * | 2020-11-22 | 2022-05-27 | Xenon Pharmaceuticals Inc. | Flunarizine for use in treating absence seizures |
| MX2023013983A (es) * | 2021-05-24 | 2023-12-12 | Cavion Inc | Metodo de tratamiento del temblor esencial. |
| AU2022329834A1 (en) | 2021-08-17 | 2024-03-07 | Korea Advanced Institute Of Science And Technology | Antisense oligonucleotide targeting cav3.1 gene and uses thereof |
| IT202100023651A1 (it) * | 2021-09-14 | 2023-03-14 | Edilio Lancellotti | Niaprazina per uso veterinario nel trattamento di disturbi del sistema nervoso centrale |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| WO2024197267A1 (en) * | 2023-03-22 | 2024-09-26 | The Regents Of The University Of Colorado, A Body Corporate | Inhibitors of ca 2+/calmodulin-dependent protein kinase ii (camkii) that do not inhibit long-term potentiation (ltp) induction and therapeutic uses thereof |
| WO2025022402A1 (en) * | 2023-07-25 | 2025-01-30 | Ariel Scientific Innovations Ltd. | Compositions and methods for treating behavior diseases |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK171349B1 (da) | 1986-11-14 | 1996-09-16 | Hoffmann La Roche | Tetrahydronaphthalenderivater, fremgangsmåde til fremstilling deraf, lægemidler indeholdende forbindelserne samt anvendelse af forbindelserne til fremstilling af lægemidler |
| AU2436792A (en) | 1991-08-16 | 1993-03-16 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
| CZ243498A3 (cs) | 1996-02-14 | 1999-09-15 | Isis Pharmaceuticals, Inc. | Oligonukleotidy s mezerou a modifikovaným cukrem |
| WO2001062740A1 (en) | 2000-02-25 | 2001-08-30 | South Alabama Medical Science Foundation | Mibefradil analogues and their use |
| US7112319B2 (en) | 2001-04-06 | 2006-09-26 | The Research Foundation Of The City University Of New York | Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using microelectrodes with microvoltammetry |
| CA2469685C (en) | 2002-01-17 | 2013-03-12 | The University Of British Columbia | Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| US20060003985A1 (en) | 2002-10-17 | 2006-01-05 | Renger John J | Enhancement of sleep with t-type calcium channel antagonists |
| US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
| AU2004224322A1 (en) | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators |
| WO2005007124A2 (en) | 2003-07-23 | 2005-01-27 | Bristol-Myers Squibb Company | Substituted dihydropyrimidine inhibitors of calcium channel function |
| US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
| KR100610731B1 (ko) | 2004-02-24 | 2006-08-09 | 한국과학기술연구원 | Ｔ-형 칼슘 채널 차단제로서 유용한 ３,４-디히드로퀴나졸린유도체 및 그의 제조 방법 |
| US7504431B2 (en) | 2004-04-16 | 2009-03-17 | Bristol-Myers Squibb Company | Sulfonyl amide inhibitors of calcium channel function |
| JP4927735B2 (ja) | 2004-08-20 | 2012-05-09 | ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン | Ｔ型カルシウムチャネル阻害剤 |
| AU2005277154B2 (en) | 2004-08-20 | 2011-11-24 | University Of Virginia Patent Foundation | T type calcium channel blockers and the treatment of diseases |
| CN101137380A (zh) | 2005-03-09 | 2008-03-05 | 默克公司 | 喹唑啉酮t-型钙通道拮抗剂 |
| US20100222387A1 (en) | 2005-06-23 | 2010-09-02 | Barrow James C | 3-Fluoro-Piperidine T-Type Calcium Channel Antagonists |
| AU2006263564A1 (en) | 2005-06-29 | 2007-01-04 | Merck Sharp & Dohme Corp. | 4-fluoro-piperidine T-type calcium channel antagonists |
| EP1906215A4 (en) | 2005-07-14 | 2012-04-18 | Teijin Chemicals Ltd | FOAM SHEET AND LIQUID CRYSTAL DISPLAY |
| KR100654328B1 (ko) | 2005-08-26 | 2006-12-08 | 한국과학기술연구원 | 피페라지닐알킬피라졸계 ｔ-타입 칼슘 채널 억제 화합물 및이의 제조방법 |
| AU2006327173A1 (en) | 2005-12-22 | 2007-06-28 | Icagen, Inc. | Calcium channel antagonists |
| PL2010493T3 (pl) | 2006-04-12 | 2016-08-31 | Merck Sharp & Dohme | Pirydyloamidy jako antagoniści kanałów wapniowych typu t |
| KR100743255B1 (ko) | 2006-05-04 | 2007-07-27 | 한국과학기술연구원 | Ｔ-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체 |
| KR100754325B1 (ko) | 2006-06-12 | 2007-09-05 | 한국과학기술연구원 | Ｔ-형 칼슘 채널 길항제로서의3-(4-클로로벤질)-4-옥소-2-티옥소-1,2,3,4-테트라히드로-퀴나졸린 유도체 |
| KR100749843B1 (ko) | 2006-07-13 | 2007-08-21 | 한국과학기술연구원 | Ｔ-타입 칼슘 채널에 억제 활성을 지닌 신규2,4-디옥소-퀴나졸린 유도체 및 이의 제조방법 |
| KR100969686B1 (ko) | 2006-08-07 | 2010-07-14 | 한국과학기술연구원 | 신규한 티아졸계 화합물 및 이를 함유하는 ｔ-형 칼슘 채널저해제 |
| CA2663501A1 (en) | 2006-09-15 | 2008-03-20 | Schering Corporation | Treating pain, diabetes, and disorders of lipid metabolism |
| US20080070888A1 (en) | 2006-09-15 | 2008-03-20 | Mckittrick Brian A | Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism |
| MX2009002918A (es) | 2006-09-15 | 2009-03-31 | Schering Corp | Derivados azetidinona y sus metodos de uso. |
| EP2061792A2 (en) | 2006-09-15 | 2009-05-27 | Schering Corporation | Azetidinone derivatives for the treatment of disorders of the lipid metabolism |
| JP2010503675A (ja) | 2006-09-15 | 2010-02-04 | シェーリング コーポレイション | 疼痛、糖尿病および脂質代謝の障害の治療に有用なスピロ縮合アゼチジン誘導体 |
| WO2008050200A1 (en) | 2006-10-24 | 2008-05-02 | Pfizer Products Inc. | Oxadiazole compounds as calcium channel antagonists |
| US20080227823A1 (en) | 2007-03-12 | 2008-09-18 | Hassan Pajouhesh | Amide derivatives as calcium channel blockers |
| CN101686952A (zh) | 2007-03-12 | 2010-03-31 | Vm生物医药公司 | 新型钙离子通道调节剂 |
| WO2008117148A1 (en) | 2007-03-23 | 2008-10-02 | Pfizer Products Inc. | Substituted oxadiazole analogs as calcium channel antagonists |
| CA2685753A1 (en) | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
| KR100863239B1 (ko) | 2007-05-23 | 2008-10-15 | 한국과학기술연구원 | 신규한 2-이미노-1,3-티아졸린계 화합물 및 이를 함유하는ｔ-형 칼슘 채널 저해제 |
| CA2692783A1 (en) | 2007-07-10 | 2009-01-15 | Merck Sharp & Dohme Corp. | Quinazolinone t-type calcium channel antagonists |
| KR101079459B1 (ko) | 2007-09-14 | 2011-11-03 | 이화여자대학교 산학협력단 | 신규한 화합물, 이의 제조방법 및 이를 포함하는 통증억제용 조성물 |
| JP2011500808A (ja) | 2007-10-24 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 複素環アミドｔ型カルシウムチャネルアンタゴニスト |
| JP5524071B2 (ja) | 2007-10-24 | 2014-06-18 | メルク・シャープ・アンド・ドーム・コーポレーション | 複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト |
| EP2211864A1 (en) | 2007-10-24 | 2010-08-04 | Merck Sharp & Dohme Corp. | Pyrazinyl amide t-type calcium channel antagonists |
| WO2009056934A1 (en) | 2007-10-31 | 2009-05-07 | Pfizer Products Inc. | 1,4-dihydronaphthyridine derivatives |
| KR100917037B1 (ko) | 2007-11-01 | 2009-09-10 | 한국과학기술연구원 | 피라졸릴카르복스아미도알킬피페라진 유도체 및 이의제조방법 |
| WO2009132454A1 (en) | 2008-04-28 | 2009-11-05 | Neuromed Pharmaceuticals Ltd. | Di-t-butylphenyl piperazines as calcium channel blockers |
| NZ589304A (en) | 2008-04-29 | 2012-03-30 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
| US8377968B2 (en) | 2008-06-02 | 2013-02-19 | Zalicus Pharmaceuticals, Ltd. | N-piperidinyl acetamide derivatives as calcium channel blockers |
| US20090298834A1 (en) | 2008-06-02 | 2009-12-03 | Hassan Pajouhesh | 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers |
| KR101014887B1 (ko) | 2008-06-26 | 2011-02-15 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 이미다졸릴알킬카르보닐유도체 및 그의 제조방법 |
| KR20100005476A (ko) | 2008-07-07 | 2010-01-15 | 한국과학기술연구원 | Ｔ-형 칼슘 채널에 활성을 지닌 신규 아이소인돌리논유도체 및 이의 제조방법 |
| US20100137403A1 (en) | 2008-07-10 | 2010-06-03 | Scott Malstrom | Method for enhancing cognition or inhibiting cognitive decline |
| KR101052620B1 (ko) | 2008-08-28 | 2011-07-29 | 한국과학기술연구원 | 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 ｔ-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물 |
| KR101052065B1 (ko) | 2008-10-15 | 2011-07-27 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법 |
| TW201028421A (en) | 2009-01-15 | 2010-08-01 | Abbott Lab | Novel benzenesulfonamides as calcium channel blockers |
| KR101905050B1 (ko) | 2009-06-05 | 2018-10-08 | 타우 쎄라퓨틱스 엘엘씨 | 암 또는 전암성 질환을 치료하기 위한 인터레이스 방법 |
| EP2476308A2 (en) | 2009-08-12 | 2012-07-18 | Carlos Alberto Barcelo Rojas | Bioelectronic system |
| JP5846372B2 (ja) | 2010-01-29 | 2016-01-20 | 国立大学法人 岡山大学 | Ｄｒａｖｅｔ症候群の発症可能性の判定方法およびその利用 |
| US8575361B2 (en) | 2010-03-02 | 2013-11-05 | Concert Pharmaceuticals Inc. | Tetrahydronaphthalene derivatives |
| WO2012032415A2 (en) | 2010-09-08 | 2012-03-15 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin |
| WO2012094612A1 (en) | 2011-01-07 | 2012-07-12 | Zenyaku Kogyo Kabushikikaisha | Method of treating essential tremor |
| KR20150013222A (ko) * | 2012-05-08 | 2015-02-04 | 자프겐 인크. | Metap2 저해제를 이용한 시상하부 비만의 치료 |
| EP2943583A4 (en) | 2013-01-10 | 2016-08-31 | Tau Therapeutics Llc | T-TYPE CALCIUM CHANNEL INHIBITORS FOR THE TREATMENT OF CANCER |
| US10292989B2 (en) | 2014-03-28 | 2019-05-21 | University Of Virginia Patent Foundation | General anesthetics that are not neurotoxic |
| KR101679262B1 (ko) | 2015-06-08 | 2016-11-24 | 한국과학기술연구원 | 4-이소프로필크로만-3-올 화합물 |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| ES2936400T3 (es) | 2015-10-22 | 2023-03-16 | Cavion Inc | Métodos para tratar el síndrome Angelman |
| SG10202111885PA (en) | 2017-04-26 | 2021-12-30 | Cavion Inc | Methods for improving memory and cognition and for treating memory and cognitive disorders |
| WO2018200844A1 (en) | 2017-04-26 | 2018-11-01 | Cavion, Inc. | Methods for treating dravet syndrome |
| GB2571978A (en) | 2018-03-15 | 2019-09-18 | Andre Fisahn | Uses, compositions and methods |
| IL282006B2 (en) | 2018-10-03 | 2023-08-01 | Cavion Inc | Treatment of bone tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
| TWI870475B (zh) | 2019-10-02 | 2025-01-21 | 美商卡凡恩公司 | 用於治療神經毒性之方法及材料 |
-
2016
- 2016-10-24 ES ES16858443T patent/ES2936400T3/es active Active
- 2016-10-24 WO PCT/US2016/058487 patent/WO2017070680A1/en not_active Ceased
- 2016-10-24 JP JP2018520430A patent/JP6957460B2/ja active Active
- 2016-10-24 AU AU2016341429A patent/AU2016341429B2/en active Active
- 2016-10-24 MX MX2018004947A patent/MX2018004947A/es unknown
- 2016-10-24 EP EP16858443.1A patent/EP3364993B1/en active Active
- 2016-10-24 CA CA3002831A patent/CA3002831C/en active Active
- 2016-10-24 FI FIEP16858443.1T patent/FI3364993T3/fi active
- 2016-10-24 DK DK16858443.1T patent/DK3364993T3/da active
- 2016-10-24 US US15/769,980 patent/US11273218B2/en active Active
-
2021
- 2021-10-06 JP JP2021164660A patent/JP2022017263A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018004947A (es) | 2018-11-09 |
| CA3002831A1 (en) | 2017-04-27 |
| US11273218B2 (en) | 2022-03-15 |
| JP6957460B2 (ja) | 2021-11-02 |
| EP3364993B1 (en) | 2022-11-09 |
| JP2022017263A (ja) | 2022-01-25 |
| FI3364993T3 (fi) | 2023-01-13 |
| AU2016341429B2 (en) | 2023-09-21 |
| US20180280357A1 (en) | 2018-10-04 |
| CA3002831C (en) | 2024-04-16 |
| AU2016341429A1 (en) | 2018-05-10 |
| EP3364993A4 (en) | 2019-08-28 |
| WO2017070680A1 (en) | 2017-04-27 |
| EP3364993A1 (en) | 2018-08-29 |
| JP2018535208A (ja) | 2018-11-29 |
| ES2936400T3 (es) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3364993T3 (da) | Fremgangsmåder til behandling af angelman syndrom | |
| DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3261721T3 (da) | Anvendelse af pridopidin til forbedring af hukommelse | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3253865T3 (da) | Fremgangsmåder til forbedring af virkningen af terapeutiske immunceller | |
| DK3331876T3 (da) | Modulators of ror-gamma | |
| HUE047477T2 (hu) | Palbociclib szilárd dózisformái | |
| DK3317400T3 (da) | Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter | |
| EP3324961C0 (en) | TREATMENT OF ANGELMAN SYNDROME WITH GABOXADOL | |
| DK3340971T3 (da) | Fremgangsmåder til behandling af lennox-gastaut syndrom ved anvendelse af fenfluramin | |
| DK3351047T3 (da) | Direkte tilgang-procedure til reduktion af latens | |
| DK3259349T3 (da) | Dehydrogenase-katalyseret fremstilling af FDCA | |
| EP3406336A4 (en) | NANO FOIL OF CORE CASE STRUCTURE TYPE | |
| DK3283210T3 (da) | Fremgangsmåde | |
| DK3132009T3 (da) | Fremgangsmåde | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| DK3512506T3 (da) | Anvendelse af pridopidin til behandling af retts syndrom | |
| DK3209317T3 (da) | Terlipressin til behandling af hepatorenalt syndrom type 1 | |
| DK3666258T3 (da) | Fremgangsmåde til behandling af prader-willis syndrom | |
| DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
| DK3368044T3 (da) | Behandling af hepatisk steatose-relateret oligo-ovulation | |
| IL246509A0 (en) | Coordinating multiple components | |
| DK3188727T3 (da) | Tasimelteon til behandling af smith-magenis¿ syndrom | |
| IL254502A0 (en) | Solid forms of menaquinols | |
| DK3201323T3 (da) | Modificering af bakteriofag |